Worth reading
46Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
4.5
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2023年6月1日〜2023年11月30日ConsolidatedJapanese GAAPNet Sales28,899¥ millionYear on year +4.5%Progress 53.3%
Operating profit618¥ millionYear on year +3.5%Progress 96.4%
Ordinary income645¥ millionYear on year +3.3%Progress 94.6%
Net income attributable to owners of the parent480¥ millionProgress 103.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share188.05円
Financial position at period-end
Total assets24,827¥ million
of which net assets 8,341 ¥ millionEquity ratio 33.5%vs. prior year-end +1.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-544
Investment-154
Financials-123
Net change-821
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥5,002 million
Segment revenueMedical device sales ¥28,844 million (YoY +4.5%), Medical Equipment Manufacturing and Sales ¥146 million (YoY +4.6%), Medical Mall Business ¥36 million (YoY +8.5%)
Segment profitMedical device sales ¥1,104 million (YoY +6.0%), Medical Equipment Manufacturing and Sales ¥6 million (YoY +116.4%), Medical Mall Business ¥2 million (YoY +436.4%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥54,215 million (YoY -6.8%)
Operating profit¥641 million (YoY -44.5%)
Ordinary income¥682 million (YoY -43.4%)
Net income¥464 million (YoY +111.8%)
Annual Dividend Forecast¥48 → ¥55
Factors Behind Changes in Business Performance
検査用機器等の設備投資需要が前年同期より増加したこと、検査・手術件数の回復により診療材料の売上が回復・増加したことにより売上高が増加し、売上増加による売上総利益の増加により営業利益が増加した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Not disclosed
Depreciation and amortization¥90 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End114 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年6月1日〜2023年11月30日 |
| Net Sales | ¥28,899 million (YoY +4.5%) |
| Operating profit | ¥618 million (YoY +3.5%) |
| Ordinary income | ¥645 million (YoY +3.3%) |
| Profit attributable to owners of the parent | ¥480 million |
| Net income per share | 188.05円 |
| Equity ratio | End of the current fiscal period 33.5 / End of previous period 32.2 |
| Total assets | ¥24,827 million |
| Net assets | ¥8,341 million |
| Cash flows from operating activities | ¥-544 million |
| Cash flows from investing activities | ¥-154 million |
| Cash flows from financing activities | ¥-123 million |
| Cash and cash equivalents at end of period | ¥5,002 million |
| Full-year earnings forecast | Net Sales ¥54,215 million (YoY -6.8%) / Operating profit ¥641 million (YoY -44.5%) / Ordinary income ¥682 million (YoY -43.4%) / Net income ¥464 million (YoY +111.8%) |
| Annual Dividend Forecast | ¥48 → ¥55 |
| Segment revenue | Medical device sales ¥28,844 million (YoY +4.5%), Medical Equipment Manufacturing and Sales ¥146 million (YoY +4.6%), Medical Mall Business ¥36 million (YoY +8.5%) |
| Segment profit | Medical device sales ¥1,104 million (YoY +6.0%), Medical Equipment Manufacturing and Sales ¥6 million (YoY +116.4%), Medical Mall Business ¥2 million (YoY +436.4%) |
| Depreciation and amortization | ¥90 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 114 Shares |
| Factors Behind Changes in Business Performance | 検査用機器等の設備投資需要が前年同期より増加したこと、検査・手術件数の回復により診療材料の売上が回復・増加したことにより売上高が増加し、売上増加による売上総利益の増加により営業利益が増加した。 |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.検査用機器などの設備投資需要が前年同期より増加したこと、検査・手術件数の回復により診療材料や医療機器消耗品の売上が回復・増加したことにより、売上高が増加した。売上増加による売上総利益の増加により営業利益も増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.